Efficacy and safety of TRPV1-related preparations in the treatment of inflammatory arthralgia

Author:

Zhou Xin1ORCID,Li Ziping1,Xing Bingfeng2

Affiliation:

1. Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China

2. The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China.

Abstract

Background: Currently, medications for the treatment of inflammatory arthralgia are limited. The role and safety of transient receptor potential vanilloid subtype 1 (TRPV1)-related preparations in reducing inflammatory arthralgia have not yet been fully established. Thus, we aimed to review the efficacy and safety of TRPV1-related preparations for the treatment of inflammatory arthralgia. Methods: We searched PubMed, Web of Science, Cochrane, and Embase databases for relevant studies, and the primary outcome was pain score (VAS, PI, NRS, and WOMAC). Results: Six randomized controlled trials involving 481 patients were analyzed. Patients with inflammatory arthralgia who received TRPV1-related preparations had lower pain scores after treatment than those who received placebo or nonsteroidal anti-inflammatory agents (standardized mean difference = –0.525; 95% confidence interval [CI], –0.789 to –0.261; P < .001). There was no significant difference in the incidence of total adverse reactions between the TRPV1-related preparations and control groups (relative risk = 1.225; 95% CI, 0.685 to 2.191; P = .494). Conclusion: TRPV1-related preparations are clinically safe and effective in the treatment of inflammatory arthralgia and are superior to placebo or nonsteroidal drugs. This may be the preferred treatment for patients with inflammatory arthralgia.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference31 articles.

1. Osteoarthritis year in review 2020: biology.;Van Den Bosch;Osteoarthritis Cartilage,2021

2. Ageing and osteoarthritis.;Sacitharan;Subcell Biochem,2019

3. The silent epidemic of chronicpain in older adults.;Domenichiello;Prog Neuropsychopharmacol Biol Psychiatry,2019

4. Optimizing pain control during the opioid epidemic.;Harbaugh;Surg Clin North Am,2019

5. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines.;Arden;Nat Rev Rheumatol,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3